EGFR x HER3 Antibody-Drug Conjugate Advances to Phase III Testing in Lung Cancer
Source Summary
An investigational EGFR x HER3 antibody-drug conjugate showed promising efficacy and tolerable safety in patients with previously treated EGFR-mutated non-small cell lung cancer. The 2.5 mg/kg dose has been selected for evaluation in the global Phase III IZABRIGHT-Lung01 registrational study.
Why it matters
Advancement to Phase III testing represents a critical milestone in the drug development pathway, bringing the therapy closer to potential regulatory approval and patient access.
